[HTML][HTML] Lung surfactant for pulmonary barrier restoration in patients with COVID-19 pneumonia

U Mirastschijski, R Dembinski, K Maedler - Frontiers in medicine, 2020 - frontiersin.org
U Mirastschijski, R Dembinski, K Maedler
Frontiers in medicine, 2020frontiersin.org
Corona virus SARS-CoV-2 has already spread around the whole world and is currently, with
no vaccine available yet, unstoppable. As per today, COVID-19 affects more than 3,000,000
confirmed patients globally. First line medications are antiviral drugs and multiple urgent
clinical trials are under way. However, a recent clinical trial testing the HIV protease inhibitor
combination lopinavir and ritonavir showed no significant antiviral activity against SARS-
CoV-2 in patients with severe disease (1). As long as we do not have specific antiviral …
Corona virus SARS-CoV-2 has already spread around the whole world and is currently, with no vaccine available yet, unstoppable. As per today, COVID-19 affects more than 3,000,000 confirmed patients globally. First line medications are antiviral drugs and multiple urgent clinical trials are under way. However, a recent clinical trial testing the HIV protease inhibitor combination lopinavir and ritonavir showed no significant antiviral activity against SARS-CoV-2 in patients with severe disease (1). As long as we do not have specific antiviral therapies against SARS-CoV-2, we need to provide supportive symptomatic therapies to prevent pulmonary failure, the most common cause of COVID-19 mortality.
Frontiers